Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Cranial Neuropathy in CIDP
    ABSTRACT & COMMENTARY

    Cranial Neuropathy in CIDP

    January 1, 2021
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    MRI of the Brachial and Lumbar Plexus Assists in the Diagnosis of CIDP

    Brief Alerts: CANOMAD; IVIG and CIDP; P0 and CIDP

    Predicting Efficacy of IVIG in CIDP

    Related Products

    Neuropathy in Myeloma

    Small Fiber Neuropathy in Critical Illness

    Prognosticating Ulnar Neuropathy at the Elbow

    Keywords

    Neuropathy

    nerves

    cidp

    demyelinating

    cranial

    By Michael Rubin, MD

    Professor of Clinical Neurology, Weill Cornell Medical College

    Dr. Rubin reports he is a consultant for Merck Sharp & Dohme Corp.

    SYNOPSIS: Cranial nerves are infrequently involved in typical chronic inflammatory demyelinating polyneuropathy, but involvement is more common in multifocal acquired demyelinating sensory and motor neuropathy (about 50%). The facial nerve is the most commonly affected cranial nerve, often bilateral.

    SOURCE: Shibuya K, Tsuneyama A, Misawa S, et al. Cranial nerve involvement in typical and atypical chronic inflammatory demyelinating polyneuropathies. Eur J Neurol 2020;27:2658-2661.

    Typically, chronic inflammatory demyelinating polyneuropathy (CIDP) presents over the course of several months, with gradually progressive symptoms of a symmetric sensorimotor polyneuropathy, with proximal and distal motor involvement exceeding sensory impairment.

    Several studies have reported tremor as a common symptom, with cranial nerve and bulbar involvement in 10% to 20% of patients, but the prevalence, characteristics, prognosis, and relations of cranial nerve palsy with CIDP subtypes have yet to be defined. A retrospective data review of 132 consecutive patients with CIDP, seen between 1984 and 2019 at Chiba University Hospital, Chiba, Japan, was undertaken to address these questions.

    All patients had been followed for at least one year and fulfilled the European Federation of Neurological Societies and Peripheral Nerve Society criteria for definite or probable CIDP. Patients with multifocal motor neuropathy, and those positive for antimyelin-associated glycoprotein (anti-MAG) or sulfated glucuronyl paragloboside antibodies were excluded.

    CIDP patients were grouped into subtypes encompassing typical CIDP (n = 89), multifocal acquired demyelinating sensory and motor neuropathy (MADSAM) (n = 31), distal acquired demyelinating symmetric neuropathy (DADS) (n = 9), and other (n = 3). Cranial nerve palsy that developed during the progressive phase of CIDP was deemed related to CIDP, but spinal accessory nerve (cranial nerve XI) involvement was excluded from evaluation, since the muscles (trapezius and sternocleidomastoid) also are innervated by upper cervical spinal nerves. Disability was assessed using the Hughes functional grading scale. Statistical analysis encompassed Fisher’s exact test and the unpaired t test, with P < 0.05 established as the level of statistical significance.

    Cranial nerve palsy was found in only 11% of both typical CIDP and DADS but was present in 48% of MADSAM patients. None of the three patients with other forms of CIDP had cranial neuropathy. Among 89 patients with typical CIDP, seven had VII nerve palsy which was bilateral in all affected, six had bulbar palsy with bilateral involvement of cranial nerves IX and X, two had bilateral trigeminal neuropathy, and one had bilateral III nerve palsy.

    Of 31 patients with MADSAM, five had bulbar palsy with involvement of cranial nerves IX and X, of which four were bilateral; four had facial palsy, which was bilateral in one; three each had a III or VI nerve palsy; two each had a V or VIII nerve palsy; and one had optic neuropathy. Only a single patient with DADS had cranial neuropathy expressed by bulbar palsy with bilateral involvement of cranial nerves IX and X.

    Cranial neuropathy recovered well in typical CIDP, despite being bilateral, whereas in MADSAM, despite being unilateral, cranial neuropathy was relatively refractory. Facial and bulbar palsy are the most common cranial nerve involvement seen in demyelinating inflammatory neuropathy, regardless of subtype.

    COMMENTARY

    Immune modulation, using intravenous immune globulin (IVIG), glucocorticoids, or plasma exchange, is the recommended initial therapy for CIDP, the choice between equals being influenced by cost, availability, venous access, comorbidities, and side effects.

    Often, those treated with IVIG require maintenance therapy. Is a higher dose of IVIG, given less frequently, better than a lower dose delivered more frequently? Among 25 CIDP patients randomized in a placebo-controlled crossover trial, receiving 20 g to 80 g of IVIG in intervals ranging from 14 to 135 days, no benefit regarding efficacy or side effect profile was appreciated with one regimen over the other.1

    REFERENCE

    1. Kuitwaard K, Brusse E, Jacobs BC, et al. Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2020; Sep 2. doi:10.1111/ene.14501. [Online ahead of print].

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 40, No. 5) - January 2021
    January 1, 2021

    Table Of Contents

    Neurotropism of COVID-19: What Is New?

    Cranial Neuropathy in CIDP

    Rapid Eye Movement Sleep Duration Is Predictive of Life Expectancy

    Rhabdomyolysis Etiology

    Medical Therapy vs. Carotid Endarterectomy in Patients with Asymptomatic Carotid Stenosis

    Ticagrelor, a New Antiplatelet Agent, Shows Promise in Secondary Prevention of Ischemic Stroke

    A Mobile Interventional Stroke Team (MIST) Shows Promise in Performing Rapid Thrombectomy

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Neurology Alert’s Editor in Chief Matthew Fink, MD; Peer Reviewer M. Flint Beal, MD; Editorial Group Manager Leslie Coplin; Editor Jason Schneider; Executive Editor Shelly Morrow Mark; and Accreditations Director Amy M. Johnson, MSN, RN, CPN, report no financial relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ReliasMedia_AR@reliasmedia.com

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2021 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing